Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer (NCT06080061) | Clinical Trial Compass
RecruitingPhase 1
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
United States45 participantsStarted 2023-10-25
Plain-language summary
The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy
* ECOG performance status of 0-2
* Age ≥ 18 years old
* Ability to understand and the willingness to personally sign the written IRB approved informed consent document
* Estimated life expectancy of 12 weeks or longer
Exclusion Criteria:
* Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist
* Age \< 18 years old
* Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree
* Diagnosis of interstitial pulmonary fibrosis
* Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields